Teva Pharmaceutical (TEVA) has partnered with Bioeq for the commercialization of a biosimilar candidate to Lucentis. Swiss company Bioeq is developing a Lucentis alternative, or biosimilar, called FYB201. It obtained exclusive commercialize rights to the drug from German company Formycon. Teva and Bioeq have agreed to work together to bring FYB201 to market. They are targeting its sale in Israel, Canada, Europe, and New Zealand.
https://www.tipranks.com/news/teva-bioeq-partner-to-sell-lucentis-biosimilar
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Teva Pharmaceutical Indu... Charts.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Teva Pharmaceutical Indu... Charts.